Storys zum Thema Health

03.11.2015 – 09:03
Debiopharm International SA
Debiopharm International SA Presents Positive Preliminary Results From Phase 1 Trials in the Development of the IAP Inhibitor Debio 1143 at the 27th EORTC-NCI-AACR Symposium in Boston
Lausanne, Switzerland (ots/PRNewswire) - Recommended Dose reached and early signs of efficacy seen Debiopharm International SA (Debiopharm) - part of Debiopharm Group(TM), a Swiss-based global biopharmaceutical company - today announced significant milestones in the clinical development of the SMAC mimetic ...
mehr
02.11.2015 – 12:02
Shire plc and Dyax Corp.
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Dublin And Burlington, Massachusetts (ots/PRNewswire) - Lead pipeline product, DX-2930, is a Phase 3-ready asset, offering potentially transformative prophylactic therapy for HAE - DX-2930 has potential to expand HAE-treated patients and achieve annual worldwide sales of up to $2 billion with exclusivity ...
mehr
29.10.2015 – 12:46
Sign Against Stroke
Sign Against Stroke Task Force Help to Address Medical, Physical, Mental and Financial Needs of People with Atrial Fibrillation with New Health Empowerment Resources
Dallas (ots/PRNewswire) - 700,000 People Worldwide Rally behind Sign Against Stroke Task Force to Call AF Care and Stroke Prevention to be Prioritised on National Health Agendas On World Stroke Day, the Sign Against Stroke (SAS) in Atrial Fibrillation Task Force introduces the enhanced SignAgainstStroke.com ...
mehr
28.10.2015 – 09:01
Daiichi Sankyo Europe GmbH
World Stroke Day: Key Risk Factors Atrial Fibrillation and Hypertension Need Detection and Treatment
Munich (ots/PRNewswire) - - On World Stroke Day (29 October) a campaign by Daiichi Sankyo highlights stroke risks associated with cardiovascular diseases - People with atrial fibrillation have a five times higher stroke risk compared to the general population.[1] In Europe less than 50% of patients with ...
mehr
27.10.2015 – 12:50
Shire Pharmaceuticals Group Plc
Shire's OPUS-3 Phase 3 Trial with Lifitegrast Meets Primary and Key Secondary Endpoints, Significantly Reducing Patient-Reported Symptoms for Dry Eye Disease
Lexington, Massachusetts (ots/PRNewswire) - Data to support lifitegrast FDA resubmission in Q1 2016; plans on track for potential 2016 launch - The topline data showed OPUS-3, a phase 3 trial, met primary endpoint, demonstrating significant improvement in patient-reported symptoms from baseline to day 84 in ...
mehr
26.10.2015 – 15:31
ViiV Healthcare
ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally
London (ots/PRNewswire) - ViiV Healthcare today awarded its first round of small grants to support men who have sex with men (MSM) and transgender community-led interventions to reduce stigma and discrimination based on sexual orientation, gender identity/expression and/or HIV status. 23 non-governmental and ...
mehr

26.10.2015 – 12:01
Resverlogix Corp.
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
Calgary, Alberta (ots/PRNewswire) - Apabetalone will be evaluated in a Phase 3 clinical trial in high-risk coronary artery disease and type 2 diabetes mellitus patients Resverlogix Corp. (the "Corporation") today announced the commencement of a Phase 3 clinical trial called 'BETonMACE' with lead drug apabetalone (RVX-208) in high-risk patients with coronary artery ...
mehr
26.10.2015 – 09:02
Janssen-Cilag AG
Janssen Receives Positive CHMP Opinion Recommending EDURANT®? (rilpivirine) for the Treatment of Adolescents Aged 12 to <18 Years with HIV-1 infection
Beerse, Belgium (ots/PRNewswire) - FOR UK AND EMEA MEDICAL MEDIA ONLY Janssen-Cilag International NV (Janssen) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a change to the terms of the marketing ...
mehr
23.10.2015 – 19:41
Teva Pharmaceutical Industries Ltd.
New Data Presented at European Society of Gynecology Congress Show Most Women Would Prefer to Have Less Frequent Periods
Prague (ots/PRNewswire) - Results from a new study at the 11th Congress of the European Society of Gynecology this week demonstrate that the majority of women in Europe prefer to have less frequent periods. The study recruited 2,883 women aged 18-45 years old from Austria, Belgium, France, Italy, Poland and ...
mehr
23.10.2015 – 12:39
Physicians Interactive, Merck, Univadis
Physicians Interactive Advances Global Health Digital Engagement by Acquiring Univadis
Reading, Massachusetts (ots/PRNewswire) - Authoritative Medical Content Platform Combined with Deep Digital Expertise Offers Greater Opportunities to Engage Healthcare Professionals and Improve Outcomes Physicians Interactive [http://www.physiciansinteractive.com ](R) (PI) announced today the launch of its recently acquired Univadis [http://www.univadis.com ] ...
mehr
21.10.2015 – 10:02
GfK SE
Insomnia Ranks 2nd After Cold as Most Common Health Complaint Internationally
Nuremberg, Germany (ots/PRNewswire) - - Findings on most common health complaints across 22 countries - Muscle pain, weight problems and migraines complete top 5 most common complaints - Women more prone to sleeping problems than men Half of people internationally say they have had a cough or cold in the last 12 months and over a quarter report suffering from ...
mehr
19.10.2015 – 13:26
Merck Healthcare Germany
Merck Unites With UNESCO to Build Research Capacity in Africa
Geneva (ots/PRNewswire) - - UNESCO-Merck Africa Research Summit aims to define interventions to prepare for the road ahead in Africa's development as an international hub for research excellence and scientific innovation - Summit will put specific emphasis on how to translate knowledge into action to improve health - Summit to be conducted on a yearly basis to ensure significant sustainable impact; 2015 edition will ...
mehr

19.10.2015 – 12:39
OrbusNeich
One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015
Hong Kong (ots/PRNewswire) - Demonstration of Clinical Effectiveness in One-year Target Lesion Failure OrbusNeich, a global company specializing in the provision of life-changing vascular solutions, has announced today the presentation of the one-year clinical outcomes from the one-thousand patient REMEDEE* Registry by Robbert de Winter, M.D., Ph.D., of the Academic ...
mehr
13.10.2015 – 09:01
Daiichi Sankyo Europe GmbH
Daiichi Sankyo Partners With World Thrombosis Day to Promote Awareness of Venous Thromboembolism and Atrial Fibrillation, Helping to Reduce Preventable Deaths
Munich (ots/PRNewswire) - World Thrombosis Day Interactive Infographic [http://af-vte.thisinfographic.com/wtd ] Daiichi Sankyo is proud to partner with World Thrombosis Day [http://www.worldthrombosisday.org ] to promote vital global awareness of thrombosis, its causes, risk factors, and signs and symptoms. ...
mehr
08.10.2015 – 08:01
Chr. Olesen Synthesis
Chr. Olesen Synthesis A/S Completes Financing
Copenhagen, Denmark (ots/PRNewswire) - Chr. Olesen Synthesis A/S, the privately held Danish manufacturer of active pharmaceutical ingredients (APIs), announced it has raised EUR10 million through the sale of Series A Preferred Stock to the American private equity firm, Signet Healthcare Partners. Chr. Olesen Synthesis, founded in the 1970's, was taken over in 2012 in a financial restructuring led by Chr. Olesen Group, a ...
mehr
06.10.2015 – 09:42
JTI Japan Tobacco International AG
JTI Calls for Transparency on Australian 'Plain' Packaging Report
Geneva (ots/PRNewswire) - Delayed Publication of Government's Post-Implementation Review Raises Concern about its Integrity The Australian Government has yet to publish its Post-Implementation Review (PIR) into 'plain' packaging for tobacco products, six months after the consultation period ended. The delay has prompted concerns that the authors of the report could ...
mehr
02.10.2015 – 12:49
United European Gastroenterology
Drinking Trends Across Europe Increasing Bowel Cancer Risk
Vienna (ots/PRNewswire) - It has been estimated that around one in 10 cases of bowel cancer can be linked to alcohol consumption[1] and the risk increases the more alcohol you drink[2]. One international group of researchers has estimated that the bowel cancer risk increases by 21% if you have two or three alcoholic drinks a day (1.5 to 6 units of alcohol) and by more than 50% if you have four or more drinks a day (6 ...
mehr
01.10.2015 – 14:02
Shire Pharmaceuticals Group Plc
Shire Announces Winners of Spotlight on Gaucher Film Contest to Mark International Gaucher Day
Zug, Switzerland (ots/PRNewswire) - Shire plc is pleased to announce the winner and runner up of the Spotlight on Gaucher film contest on the occasion of International Gaucher Day (IGD). The film contest, which was supported by the European Gaucher Alliance (EGA), encouraged people whose lives have been touched by Gaucher disease to share a video to raise awareness of ...
mehr

01.10.2015 – 09:32
Merck Healthcare Germany
Merck Agrees to Return Kuvan® Rights to BioMarin Pharmaceutical to Strengthen Focus on Core Business
Darmstadt, Germany (ots/PRNewswire) - - Agreement with BioMarin, a leading company in the treatment of genetic and rare diseases, also includes returning option to develop and commercialize Peg-Pal - Merck to receive upfront payment of EUR 340 million, plus up to EUR 185 million in additional milestones Merck, a ...
mehr
23.09.2015 – 12:12
GfK SE
Almost Three in Ten Lack Confidence in Affording Quality Life During Retirement
Nuremberg, Germany (ots/PRNewswire) - - 28 percent internationally are not confident in having enough money to live the "life they want" when they retire - While, 42 percent are confident that they will have enough money Internationally, close to three in ten (28 percent) lack confidence that they will be able to afford the life they want during retirement, ...
mehr
23.09.2015 – 11:31
ViiV Healthcare
New Phase IIIb/IV Data Show Switching to Once-Daily Triumeq® Maintains HIV Viral Suppression
London (ots/PRNewswire) - ViiV Healthcare today announced 24-week data from the Phase IIIb/IV STRIIVING study, an open-label study evaluating the efficacy, safety and tolerability of switching from an antiretroviral therapy (ART) to the once-daily, fixed-dose dolutegravir-based regimen, Triumeq(R) (abacavir/dolutegravir/lamivudine) in virologically suppressed adults ...
mehr
23.09.2015 – 01:02
Daiichi Sankyo Europe GmbH
UK's NICE Recommends Once-daily LIXIANA® (edoxaban) for Preventing Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation
Tokyo (ots/PRNewswire) - The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has recommended a new treatment to help prevent stroke and systemic embolism (SE) in patients suffering from the heart rhythm disorder atrial fibrillation (AF).[1] ...
mehr
21.09.2015 – 09:57
HOYA Vision Care
HOYA Brings Highly Accurate 3D Vision Simulation to Stores
Uithoorn, The Netherlands (ots/PRNewswire) - A leader in technology-based sales support tools, HOYA is proud to introduce its latest innovation: the HOYA Vision Simulator offers wearers the ability to experience their new lenses before they buy them, right in the store. Using wearers' actual prescription, the HOYA Vision Simulator provides a highly accurate, 3D vision experience, visualising the optical effects of the ...
mehr
21.09.2015 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives European Approval for INTUNIV®? (Guanfacine Hydrochloride Prolonged Release Tablets) as a Non-stimulant ADHD Treatment for Children and Adolescents
Zug, Switzerland (ots/PRNewswire) - The first selective alpha-2A adrenergic receptor agonist licensed for the treatment of ADHD in the EU Shire today announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant INTUNIV(R) (guanfacine hydrochloride prolonged release ...
mehr

18.09.2015 – 10:01
Astellas Pharma EMEA
Astellas Granted Label Extension for QUTENZA[TM] (capsaicin 8% patch) to Include Treatment of Diabetic Patients With Peripheral Neuropathic Pain (PNP)
Chertsey, England (ots/PRNewswire) - Astellas Pharma Europe Ltd. today announced the European Commission has granted approval for a label extension for QUTENZA[TM] (capsaicin 8% patch) to include the treatment of adult diabetic patients with peripheral neuropathic pain, either alone or in combination with other ...
mehr
17.09.2015 – 09:01
Sanofi Pasteur MSD GmbH
Sanofi Pasteur MSD Welcomes the Publication of a Special Issue on the Economic Value of Vaccination
Lyon, France (ots/PRNewswire) - A relevant and comprehensive approach on the benefits of vaccines on healthcare systems sustainability and economic growth Sanofi Pasteur MSD is proud to announce the publication of a supplement dedicated to the economic value of vaccination in the Journal of Market Access and Health Policy. The series of 7 articles has been developed ...
mehr
16.09.2015 – 18:21
Merck Healthcare
Merck Launches Partnership With Department of Health and Philippine Thyroid Association
Darmstadt, Germany And Manila, Philippines (ots/PRNewswire) - - Merck Philippines joins forces with Health Department and Thyroid Association to put spotlight on health and wellbeing of Filipino women Merck Serono, the biopharmaceutical business of Merck, today announced the launch of a partnership with the Department of Health, Philippines, and the Philippine ...
mehr
16.09.2015 – 11:17
Novo Nordisk
Victoza® (liraglutide) Provides Significantly Greater HbA1c Reduction than Lixisenatide in New Clinical Trial
Stockholm, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Abstract #75 Findings from a head-to-head trial comparing Victoza(R) (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a ...
mehr
15.09.2015 – 12:03
Novo Nordisk
New Data on Saxenda® Show Early Response Predicts Improvements in Weight Loss and Cardiometabolic Risk Factors
Stockholm, Sweden (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication Abstract #645 Today, new data from a post-hoc analysis of the phase 3a SCALE(TM) clinical development programme were presented at the 51st European Association ...
mehr
15.09.2015 – 12:01
Novo Nordisk
New Data Confirm Tresiba® U200 Delivers Significantly Lower Rates of Confirmed Hypoglycaemia Versus Insulin Glargine U100
Stockholm (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. New data presented today at the 51st annual meeting of the European Association for the Study of Diabetes (EASD) show that patients with type 2 diabetes receiving the ...
mehr

Vorherige38394041424344454647Nächste